Summary
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
History
The company was founded in 2007 by dermatologic surgeon Dr. Dexter Lee and his father, Leonard Lee, MD. It was initially known as MiMedx LLC, but MiMedx Group, Inc. was launched as a publicly traded company on the NASDAQ in 2011. The company quickly grew to become a leader in the area of tissue engineering and regenerative medicine.
Mission
MiMedx Group is committed to elevating the science and application of regenerative and tissue engineering in the service of improving patient health, outcomes and care.
Vision
MiMedx Group strives to bring meaningful advances to the field of regenerative medicine to improve the lives of patients everywhere.
Key Team
Dr. Robert Benjamin Stein M.D., Ph.D. (Pres of Regenerative Medicine & Biologics Innovation)
Mr. Scott M. Turner (Sr. VP of Operations & Procurement)
Mr. William L. Phelan (Sr. VP & Chief Accounting Officer)
Mr. Matthew M. Notarianni (Head of Investor Relations)
Mr. Mark P. Graves (Sr. VP & Chief Compliance Officer)
Hilary Dixon (VP of Investor Relations & Corp. Strategic Communications)
Ms. Kate Surdez (Chief HR Officer)
Recognition and Awards
MiMedx has been recognized with a variety of awards, including the Inc. 5000 award for the fastest-growing private companies in the US, and the CEO of the Year Award from the Biotech & Money Awards in 2019.
References
